Disc Medicine (IRON) Competitors $61.50 +0.71 (+1.17%) Closing price 04:00 PM EasternExtended Trading$61.52 +0.02 (+0.03%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRON vs. RGC, GRFS, RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, and MRUSShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Regencell Bioscience (RGC), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Disc Medicine vs. Its Competitors Regencell Bioscience Grifols Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus Disc Medicine (NASDAQ:IRON) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends. Do insiders & institutionals hold more shares of IRON or RGC? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 3.6% of Disc Medicine shares are owned by company insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, IRON or RGC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$109.36M-$4.47-13.76Regencell BioscienceN/AN/A-$4.30MN/AN/A Which has more volatility & risk, IRON or RGC? Disc Medicine has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Regencell Bioscience has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Is IRON or RGC more profitable? Regencell Bioscience's return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -26.60% -24.58% Regencell Bioscience N/A N/A N/A Do analysts recommend IRON or RGC? Disc Medicine currently has a consensus price target of $98.30, suggesting a potential upside of 59.84%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Disc Medicine is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to IRON or RGC? In the previous week, Disc Medicine had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 3 mentions for Disc Medicine and 0 mentions for Regencell Bioscience. Disc Medicine's average media sentiment score of 1.49 beat Regencell Bioscience's score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media. Company Overall Sentiment Disc Medicine Positive Regencell Bioscience Neutral SummaryDisc Medicine beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks. Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14B$3.17B$5.79B$10.48BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-13.7621.10348.9026.87Price / SalesN/A412.70521.26164.59Price / CashN/A44.8326.0131.15Price / Book4.149.8515.546.51Net Income-$109.36M-$52.82M$3.29B$271.42M7 Day Performance2.67%3.61%200.91%3.70%1 Month Performance1.91%5.51%184.43%8.10%1 Year Performance27.83%13.39%325.57%29.74% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine3.0885 of 5 stars$61.50+1.2%$98.30+59.8%+26.4%$2.14BN/A-13.7630Positive NewsRGCRegencell Bioscience0.1407 of 5 stars$14.35-2.4%N/AN/A$7.27BN/A0.0010GRFSGrifols3.9711 of 5 stars$9.63-2.5%$10.30+7.0%+8.8%$6.79B$7.81B8.2323,822Positive NewsRYTMRhythm Pharmaceuticals3.102 of 5 stars$96.03-0.2%$101.57+5.8%+81.9%$6.39B$156.29M-31.90140Positive NewsABVXAbivax2.5474 of 5 stars$85.87+2.2%$99.43+15.8%+628.3%$6.35BN/A0.0061CYTKCytokinetics4.2414 of 5 stars$49.44-3.3%$75.38+52.5%-9.5%$6.12B$18.47M-9.69250Analyst ForecastLEGNLegend Biotech3.1637 of 5 stars$33.88+2.3%$74.22+119.1%-29.9%$6.11B$627.24M-38.502,609Positive NewsAXSMAxsome Therapeutics4.8514 of 5 stars$116.78-1.4%$177.86+52.3%+21.0%$5.91B$495.03M-23.03380Positive NewsNUVLNuvalent2.9365 of 5 stars$79.37-1.4%$119.50+50.6%-29.0%$5.80BN/A-16.2040Positive NewsRNAAvidity Biosciences2.0781 of 5 stars$40.22-10.1%$68.94+71.4%-7.7%$5.76B$10.90M-11.30190Analyst ForecastAnalyst RevisionMRUSMerus2.9936 of 5 stars$68.09-2.1%$88.75+30.3%+37.3%$5.26B$36.13M-12.3837Positive News Related Companies and Tools Related Companies Regencell Bioscience Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives Cytokinetics Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Nuvalent Alternatives Avidity Biosciences Alternatives Merus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRON) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRON Stock Alerts